Computational Methods and Challenges in Cell-Free DNA Analysis for Multi-Cancer Early Detection

Krzysztof Rzecki; Marcin W. Wojewodzic; Nicko Starkey

arxiv: 2606.20174 · v1 · pith:KZ2DQAECnew · submitted 2026-06-18 · 💻 cs.LG

Computational Methods and Challenges in Cell-Free DNA Analysis for Multi-Cancer Early Detection

Nicko Starkey , Marcin W. Wojewodzic , Krzysztof Rzecki This is my paper

Pith reviewed 2026-06-26 18:05 UTC · model grok-4.3

classification 💻 cs.LG

keywords cell-free DNAmulticancer early detectionfragmentomicsepigenetic featuresmachine learningdeep learningmultimodal ensemblesclinical integration

0 comments

The pith

Multimodal ensemble approaches have the strongest promise for clinical integration in cfDNA multi-cancer early detection.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

This paper reviews computational methods developed between 2022 and 2025 for cell-free DNA analysis in multi-cancer early detection from a single blood draw. It examines extraction and analysis of fragmentomics and epigenetic features using classical statistical methods, machine learning, and deep learning models including autoencoders. Each approach is assessed for biological interpretability, validation strategy, and clinical readiness. Challenges are grouped into technical, computational, and methodological categories, with the review concluding that multimodal ensembles offer the highest readiness while standardization of protocols remains essential for progress.

Core claim

The review establishes that multimodal ensemble approaches, which integrate multiple cfDNA-derived features, demonstrate the strongest promise for clinical integration and the highest readiness among examined methods for multicancer early detection.

What carries the argument

A readiness assessment framework that evaluates methods according to biological interpretability, validation strategy, and potential for clinical integration.

If this is right

Multimodal ensemble approaches should be prioritized for further development toward clinical use.
Standardization of evaluation protocols and result reporting will enable direct comparisons across studies.
Addressing the identified technical, computational, and methodological challenges is required to advance the field.
cfDNA-based detection could extend screening to cancers that currently lack established programs.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

Wider adoption of multimodal methods could reduce the need for multiple separate screening tests if sensitivity holds in larger populations.
Standardization efforts might accelerate regulatory approval pathways by improving reproducibility of reported performance metrics.
Future work could test whether adding new feature types beyond fragmentomics and epigenetics further boosts ensemble performance.

Load-bearing premise

The methods published between 2022 and 2025 are representative of the full state of the field and the authors' categorization of challenges and readiness levels accurately reflects clinical potential without systematic bias in paper selection.

What would settle it

A head-to-head clinical validation trial that directly compares multimodal ensembles to alternative single-modality or non-ensemble methods and shows a different category achieving superior sensitivity and specificity for early-stage multi-cancer detection.

read the original abstract

Cell-free DNA (cfDNA) is a promising avenue for non-invasive multicancer early detection (MCED), in that, it can enable multiple cancer detection simultaneously from a single blood draw, with particular sensitivity to cancers that currently lack established screening programs. Here we review the computational methods developed between 2022 and 2025 for cfDNA-based MCED. We focus on how fragmentomics and epigenetic features are extracted and analyzed to detect cancer at early stages. We first briefly outline the biological basis of cfDNA signals, then review classical statistical and machine learning approaches alongside deep learning frameworks including autoencoder-based models. For each method we discuss biological interpretability, validation strategy, and readiness for clinical integration. Furthermore, we categorize the current challenges into technical, computational, and methodological while outlining open problems in the field. This review shows that multimodal ensemble approaches have the strongest promise for clinical integration and the highest readiness. However, for better assessment of future work and side-by-side comparison, standardization of evaluation protocols and reporting results will be crucial.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Desk Editor's Note private letter to a colleague

A review of 2022-2025 cfDNA MCED methods that flags multimodal ensembles as most ready but doesn't show its work on paper selection.

read the letter

The paper is a review summarizing computational methods for cell-free DNA analysis in multi-cancer early detection, covering work from 2022 to 2025. It concludes that multimodal ensemble approaches have the best shot at clinical integration.

It does a solid job of sketching the biological basis for cfDNA signals from fragmentomics and epigenetic features. Then it goes through classical statistical and machine learning techniques and deep learning models like autoencoders. For each, it notes biological interpretability, validation approaches, and how close they are to the clinic. It also groups the open challenges into technical, computational, and methodological categories. That kind of organization can be useful for someone trying to get up to speed on the area.

The main weakness is in the evidence for the headline conclusion. The abstract states that multimodal ensembles rank highest in promise and readiness, but it gives no numbers, no head-to-head comparisons, and no description of the search strategy or inclusion criteria used to pick the papers. This makes it difficult to judge whether the assessment is balanced or if it leans on a non-representative set of studies. The stress-test note correctly points out that without those details the ranking is hard to trust.

This paper is aimed at computational researchers and oncologists who follow MCED work and want a recent overview rather than a new algorithm or dataset. A reader looking for pointers to the literature might get some value, but anyone wanting rigorous evidence for prioritizing ensembles would need to dig into the cited papers themselves.

I would recommend sending it to peer review. The topic is timely and the structure is reasonable, even if the review process needs to be documented better in revision. It is not groundbreaking but it engages honestly with the recent literature.

Referee Report

2 major / 0 minor

Summary. The manuscript reviews computational methods for cfDNA-based multi-cancer early detection (MCED) published 2022-2025, covering biological signals from fragmentomics and epigenetics, classical statistical/ML approaches, and deep learning models including autoencoders. It evaluates each on interpretability, validation, and clinical readiness, categorizes challenges as technical/computational/methodological, and concludes that multimodal ensemble methods have the strongest promise for clinical integration and highest readiness, while calling for standardized evaluation protocols.

Significance. If the survey is comprehensive and the readiness rankings reproducible, the review would usefully synthesize recent cfDNA MCED literature and direct attention to multimodal ensembles as a high-readiness direction. The explicit call for standardization of evaluation protocols is a constructive contribution that could improve comparability across future studies.

major comments (2)

[Abstract] Abstract: The claim that 'multimodal ensemble approaches have the strongest promise for clinical integration and the highest readiness' is load-bearing yet unsupported by any description of literature search strategy, databases, search strings, inclusion/exclusion criteria, number of papers screened, or operationalization of 'readiness' (e.g., prospective validation, regulatory filings, head-to-head metrics). This directly affects the validity of the ranking.
[Review process] Review process (throughout): The categorization of methods and assignment of readiness levels relies on undocumented, potentially subjective criteria without explicit, reproducible scoring rules or inter-rater reliability. This is load-bearing for the central conclusion that ensembles rank highest.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for their thoughtful review and constructive comments. We address the major comments point-by-point below. Where appropriate, we have revised the manuscript to improve transparency and reproducibility of our review process.

read point-by-point responses

Referee: [Abstract] Abstract: The claim that 'multimodal ensemble approaches have the strongest promise for clinical integration and the highest readiness' is load-bearing yet unsupported by any description of literature search strategy, databases, search strings, inclusion/exclusion criteria, number of papers screened, or operationalization of 'readiness' (e.g., prospective validation, regulatory filings, head-to-head metrics). This directly affects the validity of the ranking.

Authors: We recognize that the original manuscript lacks an explicit description of the literature search methodology and the criteria used to assess clinical readiness. Although the review aimed to synthesize prominent works from 2022-2025 rather than conduct a formal systematic review, we agree that greater transparency is needed to support the central claim. In the revised version, we will add a 'Review Methodology' section that specifies the databases searched (PubMed and Google Scholar), search terms (e.g., 'cell-free DNA' AND 'multi-cancer early detection' AND 'computational methods'), inclusion criteria (peer-reviewed or preprint papers from 2022-2025 focusing on computational approaches for cfDNA MCED), and the number of papers reviewed. Additionally, we will operationalize 'readiness' using a defined framework based on validation stage (retrospective, prospective, clinical trials) and performance benchmarks reported in the literature. This will allow readers to better evaluate the ranking of multimodal ensemble approaches. revision: yes
Referee: [Review process] Review process (throughout): The categorization of methods and assignment of readiness levels relies on undocumented, potentially subjective criteria without explicit, reproducible scoring rules or inter-rater reliability. This is load-bearing for the central conclusion that ensembles rank highest.

Authors: The referee correctly identifies that the categorization and readiness assignments were not accompanied by explicit scoring rules in the original submission. To address this, we will include in the revised manuscript a supplementary table or dedicated subsection that details the criteria for method categorization (e.g., primary signal type: fragmentomics, methylation, or multimodal) and the rubric for readiness levels (e.g., Level 1: in silico or small cohort validation; Level 2: large retrospective cohorts with cross-validation; Level 3: prospective or multi-center validation with regulatory considerations). While a single-reviewer process precludes inter-rater reliability metrics, we will emphasize that assignments are derived directly from the validation strategies and results described in each cited study. We believe these additions will make the conclusion regarding multimodal ensembles more robust and reproducible without altering the substantive findings. revision: yes

Circularity Check

0 steps flagged

Review paper contains no derivations, predictions, or equations that reduce to inputs.

full rationale

This is a literature review summarizing methods from 2022-2025 without any original mathematical derivations, fitted parameters, or predictive claims that could be circular. The statement that multimodal ensembles have highest readiness is presented as a synthesis of reviewed work rather than a result obtained by construction from the paper's own inputs or self-citations. No load-bearing steps match any of the enumerated circularity patterns; the paper is self-contained as a survey.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

This is a review paper; no new free parameters, axioms, or invented entities are introduced by the authors.

pith-pipeline@v0.9.1-grok · 5717 in / 992 out tokens · 26913 ms · 2026-06-26T18:05:33.682260+00:00 · methodology

discussion (0)

Reference graph

Works this paper leans on

91 extracted references

[1]

Longitudinal cell-free dna methylome and fragmentome proﬁles in health uncover signatures of cell ty pe and demographic origin

Mio Aerden, Tatjana Jatsenko, Kaat Leroy, Kobe De Ridder, Anna Nootens, V alentina Piatti, Koen Devriendt, Joris Robert V ermeesch, Huiwen Che, and Bernard Thienpont. Longitudinal cell-free dna methylome and fragmentome proﬁles in health uncover signatures of cell ty pe and demographic origin. Genome Medicine , 2026

2026
[2]

A signal processing and deep learning framework for methylation detection using oxford nanopore sequencing

Mian Umair Ahsan, Anagha Gouru, Joe Chan, W anding Zhou, and Kai W ang. A signal processing and deep learning framework for methylation detection using oxford nanopore sequencing. Nature communications, 15(1):1448, 2024

2024
[3]

Pap smear (pap test) for cervica l cancer, n.d

American Cancer Society. Pap smear (pap test) for cervica l cancer, n.d. Accessed: 2025-08-05

2025
[4]

Dna methylation analysis explores the molecular basis of plasma cell-free dna fragmentation

Y unyun An, Xin Zhao, Ziteng Zhang, Zhaohua Xia, Mengqi Y ang, Li Ma, Y u Zhao, Gang Xu, Shunda Du, Xiang’an W u, et al. Dna methylation analysis explores the molecular basis of plasma cell-free dna fragmentation. Nature Communications , 14(1):287, 2023

2023
[5]

Genome-wide repeat landscapes in cancer and cell-free dna

Akshaya V Annapragada, Noushin Niknafs, James R White, Daniel C Bruhm, Christopher Cherry, Jamie E Medina, Vilmos Adleﬀ, Carolyn Hruban, Dimitrios Mathios, Zachariah H Foda, et al. Genome-wide repeat landscapes in cancer and cell-free dna. Science translational medicine , 16(738):eadj9283, 2024

2024
[6]

Dna methylation and machine learning: challenges and perspective toward enhanced clinical diagnostics

Erfan Aref-Eshghi, Arash B Abadi, Mohammad-Erfan Farhadieh, Amirreza Hooshmand, Fatemeh Ghasemi, Leila Y ousseﬁan, Hassan V ahidnezhad, Taylor Martin Kerrins, Xiaonan Zhao, Mahdi Akbarzadeh, et al. Dna methylation and machine learning: challenges and perspective toward enhanced clinical diagnostics. Clinical Epigenetics , 17(1):1– 43, 2025

2025
[7]

Detection of circulating tumor dna in early-and late- stage human malignancies

Chetan Bettegowda, Mark Sausen, Rebecca J Leary, Isaac Kinde, Y uxuan W ang, Nishant Agrawal, Bjarne R Bartlett, Hao W ang, Brandon Luber, Rhoda M Alani, et al. Detection of circulating tumor dna in early-and late- stage human malignancies. Science translational medicine , 6(224):224ra24–224ra24, 2014

2014
[8]

Multimodal analysis of cell-free dna whole- methylome sequencing for cancer detection and localizatio n

Fenglong Bie, Zhijie W ang, Y ulong Li, W ei Guo, Y uanyuan Hong, Tiancheng Han, Fang Lv, Shunli Y ang, Suxing Li, Xi Li, et al. Multimodal analysis of cell-free dna whole- methylome sequencing for cancer detection and localizatio n. Nature Communications , 14(1):6042, 2023

2023
[9]

Minimum information about a microarray experiment

Alvis Brazma. Minimum information about a microarray experiment. Nature Genetics , 2001

2001
[10]

The changing face of circulating tumor dna (ctdna) proﬁling: Factors tha t shape the landscape of methodologies, technologies, and 13 commercialization

Abel J Bronkhorst and Stefan Holdenrieder. The changing face of circulating tumor dna (ctdna) proﬁling: Factors tha t shape the landscape of methodologies, technologies, and 13 commercialization. Medizinische Genetik , 35(4):201–235, 2023

2023
[11]

Genomic and fragmentomic landscapes of cell-free dna for early cancer detection

Daniel C Bruhm, Nicholas A V ulpescu, Zachariah H Foda, Jillian Phallen, Robert B Scharpf, and Victor E V elculescu. Genomic and fragmentomic landscapes of cell-free dna for early cancer detection. Nature Reviews Cancer , pages 1–18, 2025

2025
[12]

Comprehensive cell type decomposition of circulating cell - free dna with celﬁe

Christa Caggiano, Barbara Celona, Fleur Garton, Joel Meﬀord, Brian L Black, Robert Henderson, Catherine Lomen-Hoerth, Andrew Dahl, and Noah Zaitlen. Comprehensive cell type decomposition of circulating cell - free dna with celﬁe. Nature communications , 12(1):2717, 2021

2021
[13]

Noninvasive lung cancer early detection via deep methylation representation learn ing

Xiangrui Cai, Jinsheng Tao, Shichao W ang, Zhiyu W ang, Jiaxian W ang, Mei Li, Hong W ang, Xixiang Tu, Hao Y ang, Jian-Bing Fan, et al. Noninvasive lung cancer early detection via deep methylation representation learn ing. In Proceedings of the AAAI Conference on Artiﬁcial Intelligence, volume 36, pages 11828–11836, 2022

2022
[14]

On over-ﬁtting in model selection and subsequent selection bias in performan ce evaluation

Gavin C Cawley and Nicola LC Talbot. On over-ﬁtting in model selection and subsequent selection bias in performan ce evaluation. The Journal of Machine Learning Research , 11:2079–2107, 2010

2079
[15]

Whole-genome proﬁling of age-and sex- associated dna methylation signatures in human plasma cell - free dna

W ei Chen, Jinjin Xu, Guodan Zeng, Rijing Ou, Changlin Y ang, Chuang Xu, Y eqin W ang, Xinxin W ang, Qiuyan Li, Chenhui Zhao, et al. Whole-genome proﬁling of age-and sex- associated dna methylation signatures in human plasma cell - free dna. Communications Medicine , 5(1):503, 2025

2025
[16]

Deep autoencoder for interpretable tissue-adaptive deconvolution and cell-ty pe- speciﬁc gene analysis

Y anshuo Chen, Yixuan W ang, Y uelong Chen, Y uqi Cheng, Y umeng W ei, Y unxiang Li, Jiuming W ang, Yingying W ei, Ting-Fung Chan, and Y u Li. Deep autoencoder for interpretable tissue-adaptive deconvolution and cell-ty pe- speciﬁc gene analysis. Nature Communications , 13(1):6735, 2022

2022
[17]

Chung, Darrell M

Daniel C. Chung, Darrell M. Gray, Harminder Singh, Rachel B. Issaka, Victoria M. Raymond, Craig Eagle, Sylvia Hu, Darya I. Chudova, AmirAli Talasaz, Joel K. Greenson, Frank A. Sinicrope, Samir Gupta, and William M. Grady. A cell-free dna blood-based test for colorectal cancer scree ning. New England Journal of Medicine , 390(11):973–983, 2024

2024
[18]

Cohen, Lu Li, Y uxuan W ang, Christopher Thoburn, Bahman Afsari, Ludmila Danilova, Christopher Douville, Ammar A

Joshua D. Cohen, Lu Li, Y uxuan W ang, Christopher Thoburn, Bahman Afsari, Ludmila Danilova, Christopher Douville, Ammar A. Javed, Fay W ong, Austin Mattox, Ralph H. Hruban, Christopher L. W olfgang, Michael G. Goggins, Marco Dal Molin, Tian-Li W ang, Richard Roden, Alison P. Klein, Janine Ptak, Lisa Dobbyn, Joy Schaefer, Natalie Silliman, Maria Popoli, J...

2018
[19]

Genome-wide cell-free dna fragmentation in patients with cancer

Stephen Cristiano, Alessandro Leal, Jillian Phallen, J acob Fiksel, Vilmos Adleﬀ, Daniel C Bruhm, Sarah Østrup Jensen, Jamie E Medina, Carolyn Hruban, James R White, et al. Genome-wide cell-free dna fragmentation in patients with cancer. Nature, 570(7761):385–389, 2019

2019
[20]

Prediction of methylation status using wgs data of plasma cfdna for multi-cancer early detection (mced)

Pin Cui, Xiaozhou Zhou, Shu Xu, W eihuang He, Guozeng Huang, Y ong Xiong, Chuxin Zhang, Tingmin Chang, Mingji Feng, Hanming Lai, et al. Prediction of methylation status using wgs data of plasma cfdna for multi-cancer early detection (mced). Clinical Epigenetics , 16(1):34, 2024

2024
[21]

Exploring circulating cell-free dna as a biomarker and as an inducer of aim2-inﬂammasome-mediated inﬂammation in patients with abdominal aortic aneurysm

Susanne Dihlmann, Carolin Kaduk, Karola H Passek, Anja Spieler, Dittmar Böckler, and Andreas S Peters. Exploring circulating cell-free dna as a biomarker and as an inducer of aim2-inﬂammasome-mediated inﬂammation in patients with abdominal aortic aneurysm. Scientiﬁc Reports , 15(1):20196, 2025

2025
[22]

Einstein, Nathan Liang, Meenakshi Malhotra, Alexey Aleshin, Solomon Moshkevich, Paul R

David J. Einstein, Nathan Liang, Meenakshi Malhotra, Alexey Aleshin, Solomon Moshkevich, Paul R. Billings, and Eirini Pectasides. Assessment of molecular remission in oligometastatic esophageal cancer with a personalized circulating tumor dna assay. JCO Precision Oncology , (4):239–243, 2020. PMID: 35050735

2020
[23]

Analysis of serum cfdna concentration and integrity before and after surgery in patients with lung cancer

Yihui Fan, Minxin Shi, Saihua Chen, Guanjun Ju, Lingxian g Chen, Haimin Lu, Jian Chen, and Shiying Zheng. Analysis of serum cfdna concentration and integrity before and after surgery in patients with lung cancer. Cellular and Molecular Biology, 65(6):56–63, 2019

2019
[24]

Whole-genome bisulﬁte sequencing analysis of circulating tumour dna for the detection and molecular classiﬁcation of cancer

Yibo Gao, Hengqiang Zhao, Ke An, Zongzhi Liu, Luo Hai, Renda Li, Y ang Zhou, W eipeng Zhao, Y ongsheng Jia, Nan W u, et al. Whole-genome bisulﬁte sequencing analysis of circulating tumour dna for the detection and molecular classiﬁcation of cancer. Clinical and Translational Medicine, 12(8):e1014, 2022

2022
[25]

Cell-free dna in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls

Mary Beth Giacona, George C Ruben, Kenneth A Iczkowski, Thomas B Roos, Donna M Porter, and George D Sorenson. Cell-free dna in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas, 17(1):89–97, 1998

1998
[26]

Exposure-inducible genes may contribute to missingness in rnaseq-based gene expression analyses

Olga Y Gorlova, Ivan P Gorlov, R Taylor Ripley, Chao Cheng, Y afang Li, Bo Peng, Y anhong Liu, Hee-Jin Jang, Sung W ook Kang, Claire Lee, et al. Exposure-inducible genes may contribute to missingness in rnaseq-based gene expression analyses. Scientiﬁc Reports , 15(1):30889, 2025

2025
[27]

Bisulﬁte genomic sequencing: systematic investigation of critical experimental parameters

Christoph Grunau, SJ Clark, and André Rosenthal. Bisulﬁte genomic sequencing: systematic investigation of critical experimental parameters. Nucleic acids research , 29(13):e65–e65, 2001

2001
[28]

Cel l- free dna and apoptosis: how dead cells inform about the living

Ellen Heitzer, Lisa Auinger, and Michael R Speicher. Cel l- free dna and apoptosis: how dead cells inform about the living. Trends in molecular medicine , 26(5):519–528, 2020

2020
[29]

Deciphering response dynamics and treatment resistance from circulati ng tumor dna after car t-cells in multiple myeloma

Hitomi Hosoya, Mia Carleton, Kailee Tanaka, Brian Sword er, Shriya Syal, Bita Sahaf, Alisha M Maltos, Oscar Silva, Henning Stehr, V anna Hovanky, et al. Deciphering response dynamics and treatment resistance from circulati ng tumor dna after car t-cells in multiple myeloma. Nature Communications, 16(1):1824, 2025

2025
[30]

Prediction of dna methylation based on multi-dimensional feature encoding and double convolutional fully connected convolutional neural network

W enxing Hu, Lixin Guan, and Mengshan Li. Prediction of dna methylation based on multi-dimensional feature encoding and double convolutional fully connected convolutional neural network. PLoS Computational Biology, 19(8):e1011370, 2023

2023
[31]

Plasma circulating cell-free dna integrity as a promising biomark er for diagnosis and surveillance in patients with hepatocell ular carcinoma

Ao Huang, Xin Zhang, Shao-Lai Zhou, Y a Cao, Xiao-W u Huang, Jia Fan, Xin-Rong Y ang, and Jian Zhou. Plasma circulating cell-free dna integrity as a promising biomark er for diagnosis and surveillance in patients with hepatocell ular carcinoma. Journal of Cancer , 7(13):1798, 2016. 14

2016
[32]

Bioinformatics analysis for circulating cell-free dna in c ancer

Chiang-Ching Huang, Meijun Du, and Liang W ang. Bioinformatics analysis for circulating cell-free dna in c ancer. Cancers, 11(6):805, 2019

2019
[33]

Getting ready for the european health data space (ehds): Iderha’s plan to align with the latest ehd s requirements for the secondary use of health data

Rada Hussein, Irina Balaur, Anja Burmann, Hanna Ćwiek- Kupczyńska, Y ojana Gadiya, Soumyabrata Ghosh, Prabath Jayathissa, Florian Katsch, Andreas Kremer, Jaakko Lähteenmäki, et al. Getting ready for the european health data space (ehds): Iderha’s plan to align with the latest ehd s requirements for the secondary use of health data. Open Research Europe, 4...

2024
[34]

Transforming cancer screening: the potential of multi-can cer early detection (mced) technologies

Mitsuho Imai, Y oshiaki Nakamura, and Takayuki Y oshino. Transforming cancer screening: the potential of multi-can cer early detection (mced) technologies. International Journal of Clinical Oncology , 30(2):180–193, 2025

2025
[35]

Deconvolution of cell-free dna in cancer liquid biopsy using a deep autoencoder

Felix Jackson and Thomas Lukasiewicz. Deconvolution of cell-free dna in cancer liquid biopsy using a deep autoencoder. In Proceedings of the 14th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics , pages 1–6, 2023

2023
[36]

Dna fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells

Sabine Jahr, Hannes Hentze, Sabine Englisch, Dieter Har dt, Frank O Fackelmayer, Rolf-Dieter Hesch, and Rolf Knippers. Dna fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer research, 61(4):1659–1665, 2001

2001
[37]

Leveraging cfdna fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma

Zichen Jiao, Xiaoqiang Zhang, Y ulong Xuan, Xiaoming Shi , Zirui Zhang, Ao Y u, Ningyou Li, Shanshan Y ang, Xiaofeng He, Gefei Zhao, et al. Leveraging cfdna fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma. Cell Reports Medicine , 5(8), 2024

2024
[38]

Detect ing cell-of-origin and cancer-speciﬁc methylation features o f cell- free dna from nanopore sequencing

Efrat Katsman, Shari Orlanski, Filippo Martignano, Ila na Fox-Fisher, Ruth Shemer, Y uval Dor, A viad Zick, Amir Eden, Iacopo Petrini, Silvestro G Conticello, et al. Detect ing cell-of-origin and cancer-speciﬁc methylation features o f cell- free dna from nanopore sequencing. Genome Biology , 23(1):158, 2022

2022
[39]

Deep learning model integrating cfdna methylation and fragment size proﬁles for lung cancer diagnosis

Minjung Kim, Juntae Park, Seonghee Oh, Byeong-Ho Jeong, Y uree Byun, Sun Hye Shin, Y unjoo Im, Jong Ho Cho, and Eun-Hae Cho. Deep learning model integrating cfdna methylation and fragment size proﬁles for lung cancer diagnosis. Scientiﬁc reports , 14(1):14797, 2024

2024
[40]

To impute or not to impute in untargeted metabolomics that is the compositional question

Dennis D Krutkin, Sydney Thomas, Simone Zuﬀa, Prajit Rajkumar, Rob Knight, Pieter C Dorrestein, and Scott T Kelley. To impute or not to impute in untargeted metabolomics that is the compositional question. Journal of the American Society for Mass Spectrometry , 36(4):742– 759, 2025

2025
[41]

Single-molecule methylation proﬁles of cell-free dna in ca ncer with nanopore sequencing

Billy T Lau, Alison Almeda, Marie Schauer, Madeline McNamara, Xiangqi Bai, Qingxi Meng, Mira Partha, Susan M Grimes, HoJoon Lee, Gregory M Heestand, et al. Single-molecule methylation proﬁles of cell-free dna in ca ncer with nanopore sequencing. Genome Medicine , 15(1):33, 2023

2023
[42]

Impact of clinical variables on cfdna fragmentomic signatures and their potential as confounder s in cancer detection

Tae-Rim Lee, Eun Hye Cho, Jin Mo Ahn, Junnam Lee, Chang-Seok Ki, Byeong-Ho Jeong, Min-Jung Kwon, and Eun-Hae Cho. Impact of clinical variables on cfdna fragmentomic signatures and their potential as confounder s in cancer detection. Clinical Chemistry , 72(2):254–265, 2026

2026
[43]

Free dna in the serum of cancer patients and the eﬀect of therapy

SA Leon, B Shapiro, DM Sklaroﬀ, and MJ Y aros. Free dna in the serum of cancer patients and the eﬀect of therapy. Cancer research, 37(3):646–650, 1977

1977
[44]

Dismir: Deep learning-based noninvasive cancer detection by integrating dna sequence and methylation information of individual cell-free dna reads

Jiaqi Li, Lei W ei, Xianglin Zhang, W ei Zhang, Haochen W ang, Bixi Zhong, Zhen Xie, Hairong Lv, and Xiaowo W ang. Dismir: Deep learning-based noninvasive cancer detection by integrating dna sequence and methylation information of individual cell-free dna reads. Brieﬁngs in bioinformatics , 22(6), 2021

2021
[45]

Comprehensive tissue deconvolution of cell-free dna by deep learning for disease diagnosis and monitoring

Shuo Li, W eihua Zeng, Xiaohui Ni, Qiao Liu, W enyuan Li, Mary L Stackpole, Y onggang Zhou, Arjan Gower, Kostyantyn Krysan, Preeti Ahuja, et al. Comprehensive tissue deconvolution of cell-free dna by deep learning for disease diagnosis and monitoring. Proceedings of the National Academy of Sciences , 120(28):e2305236120, 2023

2023
[46]

Detection of dna base modiﬁcations by deep recurrent neural network on oxford nanopore sequencing data

Qian Liu, Li Fang, Guoliang Y u, Depeng W ang, Chuan-Le Xiao, and Kai W ang. Detection of dna base modiﬁcations by deep recurrent neural network on oxford nanopore sequencing data. Nature communications, 10(1):2449, 2019

2019
[47]

Finaleme: Predicting dna methylation by the fragmentation patterns of plasma cell-free dna

Y aping Liu, Sarah C Reed, Christopher Lo, Atish D Choudhury, Heather A Parsons, Daniel G Stover, Gavin Ha, Gregory Gydush, Justin Rhoades, Denisse Rotem, et al. Finaleme: Predicting dna methylation by the fragmentation patterns of plasma cell-free dna. Nature communications , 15(1):2790, 2024

2024
[48]

A dna methylation atlas of normal human cell types

Netanel Loyfer, Judith Magenheim, A yelet Peretz, Gordo n Cann, Joerg Bredno, Agnes Klochendler, Ilana Fox-Fisher, Sapir Shabi-Porat, Merav Hecht, Tsuria Pelet, et al. A dna methylation atlas of normal human cell types. Nature, 613(7943):355–364, 2023

2023
[49]

Autoencoded dna methylation data to predict breast cancer recurrence: Machine learning models and gene-weigh t signiﬁcance

Laura Macías-García, María Martínez-Ballesteros, José María Luna-Romera, José M García-Heredia, Jorge García-Gutiérrez, and José C Riquelme-Santos. Autoencoded dna methylation data to predict breast cancer recurrence: Machine learning models and gene-weigh t signiﬁcance. Artiﬁcial Intelligence in Medicine , 110:101976, 2020

2020
[50]

Post-menopausal breast cancer: from estrogen to androgen receptor

A visek Majumder, Mahavir Singh, and Suresh C Tyagi. Post-menopausal breast cancer: from estrogen to androgen receptor. Oncotarget, 8(60):102739, 2017

2017
[51]

Clinical variables and cell-free dna fragmentomics: Biological and clinical insi ghts

Y asine Malki and Y M Dennis Lo. Clinical variables and cell-free dna fragmentomics: Biological and clinical insi ghts. Clinical Chemistry , 72(2):219–221, 02 2026

2026
[52]

Les acides nucleiques du plasma sanguin chez 1 homme

P Mandel. Les acides nucleiques du plasma sanguin chez 1 homme. CR Seances Soc Biol Fil , 142:241–243, 1948

1948
[53]

The european health data space

J Scott Marcus, Bertin Martens, Christophe Carugati, An ne Bucher, and Ilsa Godlovitch. The european health data space. IPOL| policy department for economic, scientiﬁc and quality of life policies, European Parliament Policy Department studies , 2022

2022
[54]

Clinical value of plasma cfdna concentration and integrity in breast cancer patients

Y ajun Miao, Yingrui Fan, Liang Zhang, Tingting Ma, and Rong Li. Clinical value of plasma cfdna concentration and integrity in breast cancer patients. Cellular and Molecular Biology, 65(6):64–72, 2019

2019
[55]

Preoperative cell-free dna concentration in plasma as a diagnostic and prognostic biomarker of clear cell renal cell carcinoma

Tomasz Milecki, Katarzyna Kluzek, Natalia Pstrąg, Andr zej Antczak, W ojciech Cieślikowski, Mateusz Wichtowski, Łukasz Kuncman, Zbigniew Kwias, and Joanna W esoły. Preoperative cell-free dna concentration in plasma as a diagnostic and prognostic biomarker of clear cell renal cell carcinoma. Contemporary Oncology/Współczesna Onkologia, 27(4):284–291, 2023

2023
[56]

Technology and future of multi-cancer early detection

Danny A Milner Jr and Jochen K Lennerz. Technology and future of multi-cancer early detection. Life, 14(7):833, 2024. 15

2024
[57]

Spalding, Giora Landesberg, A viad Zick, Albert Grinshpun, AM James Shapiro, Markus Grompe, A vigail Dreazan Wittenberg, Benjamin Glaser, Ruth Shemer, Tommy Kaplan, and Y uval Dor

Joshua Moss, Judith Magenheim, Daniel Neiman, Hai Zemmour, Netanel Loyfer, Amit Korach, Y aacov Samet, Myriam Maoz, Henrik Druid, Peter Arner, Keng-Y eh Fu, Endre Kiss, Kirsty L. Spalding, Giora Landesberg, A viad Zick, Albert Grinshpun, AM James Shapiro, Markus Grompe, A vigail Dreazan Wittenberg, Benjamin Glaser, Ruth Shemer, Tommy Kaplan, and Y uval Do...

2018
[58]

An ultrasensitive method for quantitating circulating tumor dna with broad patient coverage

Aaron M Newman, Scott V Bratman, Jacqueline To, Jacob F W ynne, Neville CW Eclov, Leslie A Modlin, Chih Long Liu, Joel W Neal, Heather A W akelee, Robert E Merritt, et al. An ultrasensitive method for quantitating circulating tumor dna with broad patient coverage. Nature medicine , 20(5):548– 554, 2014

2014
[59]

Appraising clinical applicability of studies: mapping and synthesis o f current frameworks, and proposal of the fracas framework and vicort checklist

Quoc Dinh Nguyen, Erica M Moodie, Philippe Desmarais, Robert Goulden, Marie-France Forget, Eric Peters, Sahar Saeed, Mark R Keezer, and Christina W olfson. Appraising clinical applicability of studies: mapping and synthesis o f current frameworks, and proposal of the fracas framework and vicort checklist. BMC medical research methodology , 21(1):248, 2021

2021
[60]

Trong Hieu Nguyen, Nhu Nhat Tan Doan, Trung Hieu Tran, Le Anh Khoa Huynh, Phuoc Loc Doan, Thi Hue Hanh Nguyen, V an Thien Chi Nguyen, Giang Thi Huong Nguyen, Hoai-Nghia Nguyen, Hoa Giang, et al. Tissue of origin detection for cancer tumor using low-depth cfdna samples through combination of tumor-speciﬁc methylation atlas an d genome-wide methylation dens...

2024
[61]

Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation

Michaël Noë, Dimitrios Mathios, Akshaya V Annapragada, Shashikant Koul, Zacharia H Foda, Jamie E Medina, Stephen Cristiano, Christopher Cherry, Daniel C Bruhm, Noushin Niknafs, et al. Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation. Nature communications, 15(1):6690, 2024

2024
[62]

Mai-Britt W orm Ørntoft, Sarah Østrup Jensen, Nadia Øgaard, Tenna V esterman Henriksen, Linnea Ferm, Ib Jarle Christensen, Thomas Reinert, Ole Halfdan Larsen, Hans Jørgen Nielsen, and Claus Lindbjerg Andersen. Age- stratiﬁed reference intervals unlock the clinical potenti al of circulating cell-free dna as a biomarker of poor outcome for healthy individua...

2021
[63]

Metdecode: methylation-based deconvolution of cell-free dna for noninvasive multi-cancer typing

Antoine Passemiers, Stefania Tuveri, Dhanya Sudhakara n, Tatjana Jatsenko, Tina Laga, Kevin Punie, Sigrid Hatse, Sabine Tejpar, An Coosemans, Els V an Nieuwenhuysen, et al. Metdecode: methylation-based deconvolution of cell-free dna for noninvasive multi-cancer typing. Bioinformatics, 40(9):btae522, 2024

2024
[64]

Early detection of renal cell carcinoma: a novel cell-free dna fragmentomic s- based liquid biopsy assay

YL Peng, B Y u, TX Huang, ZH Zhou, H Zhang, WXF Tang, XX Xu, DQ Zhu, R W Y ang, H Bao, et al. Early detection of renal cell carcinoma: a novel cell-free dna fragmentomic s- based liquid biopsy assay. ESMO open , 10(7):105323, 2025

2025
[65]

Artiﬁcial intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine

Karishma Sahoo, Prakash Lingasamy, Masuma Khatun, Sajitha Lulu Sudhakaran, Andres Salumets, Vino Sundararajan, and Vijayachitra Modhukur. Artiﬁcial intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine. Epigenetics & Chromatin, 18(1):35, 2025

2025
[66]

Computational challenges in detection of cancer using cell-free dna methylation

Madhu Sharma, Rohit Kumar V erma, Sunil Kumar, and Vibhor Kumar. Computational challenges in detection of cancer using cell-free dna methylation. Computational and Structural Biotechnology Journal , 20:26–39, 2022

2022
[67]

Development of a deep learning model for cancer diagnosis by inspecting cell-free dna end-motifs

Hongru Shen, Meng Y ang, Jilei Liu, Kexin Chen, and Xiangchun Li. Development of a deep learning model for cancer diagnosis by inspecting cell-free dna end-motifs. NPJ Precision Oncology, 8(1):160, 2024

2024
[68]

Integrating liquid biopsies into the management of cancer

Giulia Siravegna, Silvia Marsoni, Salvatore Siena, and Alberto Bardelli. Integrating liquid biopsies into the management of cancer. Nature reviews Clinical oncology , 14(9):531–548, 2017

2017
[69]

Circulating tumor nucleic acids: biology, release mechani sms, and clinical relevance

Pavel Stejskal, Hani Goodarzi, Josef Srovnal, Marián Hajdúch, Laura J van’t V eer, and Mark Jesus M Magbanua. Circulating tumor nucleic acids: biology, release mechani sms, and clinical relevance. Molecular cancer, 22(1):15, 2023

2023
[70]

Genome-wide cfdna methylation proﬁling reveals robust hypermethylation signatures in ovarian cancer

Simone Karlsson Terp, Karen Guldbrandsen, Malene Pontoppidan Stoico, Lasse Ringsted Mark, Anna Poulsgaard Frandsen, Karen Dybkær, and Inge Søkilde Pedersen. Genome-wide cfdna methylation proﬁling reveals robust hypermethylation signatures in ovarian cancer. Cancers, 17(12):2026, 2025

2026
[71]

Origins, structures, and functions of circulatin g dna in oncology

Alain R Thierry, S El Messaoudi, PB Gahan, P Anker, and M Stroun. Origins, structures, and functions of circulatin g dna in oncology. Cancer and metastasis reviews , 35:347– 376, 2016

2016
[72]

Artiﬁcial intelligence and machine learning i n cell-free-dna-based diagnostics

WH Adrian Tsui, Spencer C Ding, Peiyong Jiang, and YM Dennis Lo. Artiﬁcial intelligence and machine learning i n cell-free-dna-based diagnostics. Genome Research, 35(1):1– 19, 2025

2025
[73]

There is no such thing as a validated prediction model

Ben V an Calster, Ewout W Steyerberg, Laure W ynants, and Maarten V an Smeden. There is no such thing as a validated prediction model. BMC medicine , 21(1):70, 2023

2023
[74]

Critical factors in the analytical work ﬂow of circulating tumor dna-based molecular proﬁling

Paul van der Leest and Ed Schuuring. Critical factors in the analytical work ﬂow of circulating tumor dna-based molecular proﬁling. Clinical Chemistry , 70(1):220–233, 01 2024

2024
[75]

Cancer treatment monitoring using cell-free dna fragmentomes

Iris van’t Erve, Bahar Alipanahi, Keith Lumbard, Zachar y L Skidmore, Lorenzo Rinaldi, Laurel K Millberg, Jacob Carey, Bryan Chesnick, Stephen Cristiano, Carter Portwood , et al. Cancer treatment monitoring using cell-free dna fragmentomes. Nature communications, 15(1):8801, 2024

2024
[76]

Liquid biopsie s come of age: towards implementation of circulating tumour dna

Jonathan CM W an, Charles Massie, Javier Garcia-Corbach o, Florent Mouliere, James D Brenton, Carlos Caldas, Simon Pacey, Richard Baird, and Nitzan Rosenfeld. Liquid biopsie s come of age: towards implementation of circulating tumour dna. Nature Reviews Cancer , 17(4):223–238, 2017

2017
[77]

Increased plasma dna integrity in cancer patients

Brant G W ang, Han-Y ao Huang, Y u-Chi Chen, Robert E Bristow, Keyanunoosh Kassauei, Chih-Chien Cheng, Richard Roden, Lori J Sokoll, Daniel W Chan, and Ie-Ming Shih. Increased plasma dna integrity in cancer patients. Cancer research, 63(14):3966–3968, 2003

2003
[78]

cfdecon: Accurate and interpretable methylation-based ce ll type deconvolution for cell-free dna

Yixuan W ang, Jiayi Li, Jingqi Li, Shen Y ang, Y uhan Huang, Xinyuan Liu, Yimin Fan, Irwin King, Y umei Li, and Y u Li. cfdecon: Accurate and interpretable methylation-based ce ll type deconvolution for cell-free dna. bioRxiv, pages 2025–02, 2025

2025
[79]

The analysis of cell-free dna 16 concentrations and integrity in serum of initial and treate d of lymphoma patients

Jianqiu W u, W eiyan Tang, Laiquan Huang, Ning Hou, Jing W u, Xianfeng Cheng, Dawei Ma, Pudong Qian, Qian Shen, W enjie Guo, et al. The analysis of cell-free dna 16 concentrations and integrity in serum of initial and treate d of lymphoma patients. Clinical Biochemistry , 63:59–65, 2019

2019
[80]

A systematic review of biologically-informed deep learning models for cancer: fundamental trends for encoding and interpreting oncology data

Magdalena W ysocka, Oskar W ysocki, Marie Zuﬀerey, Dónal Landers, and André Freitas. A systematic review of biologically-informed deep learning models for cancer: fundamental trends for encoding and interpreting oncology data. BMC bioinformatics , 24(1):198, 2023

2023

Showing first 80 references.

[1] [1]

Longitudinal cell-free dna methylome and fragmentome proﬁles in health uncover signatures of cell ty pe and demographic origin

Mio Aerden, Tatjana Jatsenko, Kaat Leroy, Kobe De Ridder, Anna Nootens, V alentina Piatti, Koen Devriendt, Joris Robert V ermeesch, Huiwen Che, and Bernard Thienpont. Longitudinal cell-free dna methylome and fragmentome proﬁles in health uncover signatures of cell ty pe and demographic origin. Genome Medicine , 2026

2026

[2] [2]

A signal processing and deep learning framework for methylation detection using oxford nanopore sequencing

Mian Umair Ahsan, Anagha Gouru, Joe Chan, W anding Zhou, and Kai W ang. A signal processing and deep learning framework for methylation detection using oxford nanopore sequencing. Nature communications, 15(1):1448, 2024

2024

[3] [3]

Pap smear (pap test) for cervica l cancer, n.d

American Cancer Society. Pap smear (pap test) for cervica l cancer, n.d. Accessed: 2025-08-05

2025

[4] [4]

Dna methylation analysis explores the molecular basis of plasma cell-free dna fragmentation

Y unyun An, Xin Zhao, Ziteng Zhang, Zhaohua Xia, Mengqi Y ang, Li Ma, Y u Zhao, Gang Xu, Shunda Du, Xiang’an W u, et al. Dna methylation analysis explores the molecular basis of plasma cell-free dna fragmentation. Nature Communications , 14(1):287, 2023

2023

[5] [5]

Genome-wide repeat landscapes in cancer and cell-free dna

Akshaya V Annapragada, Noushin Niknafs, James R White, Daniel C Bruhm, Christopher Cherry, Jamie E Medina, Vilmos Adleﬀ, Carolyn Hruban, Dimitrios Mathios, Zachariah H Foda, et al. Genome-wide repeat landscapes in cancer and cell-free dna. Science translational medicine , 16(738):eadj9283, 2024

2024

[6] [6]

Dna methylation and machine learning: challenges and perspective toward enhanced clinical diagnostics

Erfan Aref-Eshghi, Arash B Abadi, Mohammad-Erfan Farhadieh, Amirreza Hooshmand, Fatemeh Ghasemi, Leila Y ousseﬁan, Hassan V ahidnezhad, Taylor Martin Kerrins, Xiaonan Zhao, Mahdi Akbarzadeh, et al. Dna methylation and machine learning: challenges and perspective toward enhanced clinical diagnostics. Clinical Epigenetics , 17(1):1– 43, 2025

2025

[7] [7]

Detection of circulating tumor dna in early-and late- stage human malignancies

Chetan Bettegowda, Mark Sausen, Rebecca J Leary, Isaac Kinde, Y uxuan W ang, Nishant Agrawal, Bjarne R Bartlett, Hao W ang, Brandon Luber, Rhoda M Alani, et al. Detection of circulating tumor dna in early-and late- stage human malignancies. Science translational medicine , 6(224):224ra24–224ra24, 2014

2014

[8] [8]

Multimodal analysis of cell-free dna whole- methylome sequencing for cancer detection and localizatio n

Fenglong Bie, Zhijie W ang, Y ulong Li, W ei Guo, Y uanyuan Hong, Tiancheng Han, Fang Lv, Shunli Y ang, Suxing Li, Xi Li, et al. Multimodal analysis of cell-free dna whole- methylome sequencing for cancer detection and localizatio n. Nature Communications , 14(1):6042, 2023

2023

[9] [9]

Minimum information about a microarray experiment

Alvis Brazma. Minimum information about a microarray experiment. Nature Genetics , 2001

2001

[10] [10]

The changing face of circulating tumor dna (ctdna) proﬁling: Factors tha t shape the landscape of methodologies, technologies, and 13 commercialization

Abel J Bronkhorst and Stefan Holdenrieder. The changing face of circulating tumor dna (ctdna) proﬁling: Factors tha t shape the landscape of methodologies, technologies, and 13 commercialization. Medizinische Genetik , 35(4):201–235, 2023

2023

[11] [11]

Genomic and fragmentomic landscapes of cell-free dna for early cancer detection

Daniel C Bruhm, Nicholas A V ulpescu, Zachariah H Foda, Jillian Phallen, Robert B Scharpf, and Victor E V elculescu. Genomic and fragmentomic landscapes of cell-free dna for early cancer detection. Nature Reviews Cancer , pages 1–18, 2025

2025

[12] [12]

Comprehensive cell type decomposition of circulating cell - free dna with celﬁe

Christa Caggiano, Barbara Celona, Fleur Garton, Joel Meﬀord, Brian L Black, Robert Henderson, Catherine Lomen-Hoerth, Andrew Dahl, and Noah Zaitlen. Comprehensive cell type decomposition of circulating cell - free dna with celﬁe. Nature communications , 12(1):2717, 2021

2021

[13] [13]

Noninvasive lung cancer early detection via deep methylation representation learn ing

Xiangrui Cai, Jinsheng Tao, Shichao W ang, Zhiyu W ang, Jiaxian W ang, Mei Li, Hong W ang, Xixiang Tu, Hao Y ang, Jian-Bing Fan, et al. Noninvasive lung cancer early detection via deep methylation representation learn ing. In Proceedings of the AAAI Conference on Artiﬁcial Intelligence, volume 36, pages 11828–11836, 2022

2022

[14] [14]

On over-ﬁtting in model selection and subsequent selection bias in performan ce evaluation

Gavin C Cawley and Nicola LC Talbot. On over-ﬁtting in model selection and subsequent selection bias in performan ce evaluation. The Journal of Machine Learning Research , 11:2079–2107, 2010

2079

[15] [15]

Whole-genome proﬁling of age-and sex- associated dna methylation signatures in human plasma cell - free dna

W ei Chen, Jinjin Xu, Guodan Zeng, Rijing Ou, Changlin Y ang, Chuang Xu, Y eqin W ang, Xinxin W ang, Qiuyan Li, Chenhui Zhao, et al. Whole-genome proﬁling of age-and sex- associated dna methylation signatures in human plasma cell - free dna. Communications Medicine , 5(1):503, 2025

2025

[16] [16]

Deep autoencoder for interpretable tissue-adaptive deconvolution and cell-ty pe- speciﬁc gene analysis

Y anshuo Chen, Yixuan W ang, Y uelong Chen, Y uqi Cheng, Y umeng W ei, Y unxiang Li, Jiuming W ang, Yingying W ei, Ting-Fung Chan, and Y u Li. Deep autoencoder for interpretable tissue-adaptive deconvolution and cell-ty pe- speciﬁc gene analysis. Nature Communications , 13(1):6735, 2022

2022

[17] [17]

Chung, Darrell M

Daniel C. Chung, Darrell M. Gray, Harminder Singh, Rachel B. Issaka, Victoria M. Raymond, Craig Eagle, Sylvia Hu, Darya I. Chudova, AmirAli Talasaz, Joel K. Greenson, Frank A. Sinicrope, Samir Gupta, and William M. Grady. A cell-free dna blood-based test for colorectal cancer scree ning. New England Journal of Medicine , 390(11):973–983, 2024

2024

[18] [18]

Cohen, Lu Li, Y uxuan W ang, Christopher Thoburn, Bahman Afsari, Ludmila Danilova, Christopher Douville, Ammar A

Joshua D. Cohen, Lu Li, Y uxuan W ang, Christopher Thoburn, Bahman Afsari, Ludmila Danilova, Christopher Douville, Ammar A. Javed, Fay W ong, Austin Mattox, Ralph H. Hruban, Christopher L. W olfgang, Michael G. Goggins, Marco Dal Molin, Tian-Li W ang, Richard Roden, Alison P. Klein, Janine Ptak, Lisa Dobbyn, Joy Schaefer, Natalie Silliman, Maria Popoli, J...

2018

[19] [19]

Genome-wide cell-free dna fragmentation in patients with cancer

Stephen Cristiano, Alessandro Leal, Jillian Phallen, J acob Fiksel, Vilmos Adleﬀ, Daniel C Bruhm, Sarah Østrup Jensen, Jamie E Medina, Carolyn Hruban, James R White, et al. Genome-wide cell-free dna fragmentation in patients with cancer. Nature, 570(7761):385–389, 2019

2019

[20] [20]

Prediction of methylation status using wgs data of plasma cfdna for multi-cancer early detection (mced)

Pin Cui, Xiaozhou Zhou, Shu Xu, W eihuang He, Guozeng Huang, Y ong Xiong, Chuxin Zhang, Tingmin Chang, Mingji Feng, Hanming Lai, et al. Prediction of methylation status using wgs data of plasma cfdna for multi-cancer early detection (mced). Clinical Epigenetics , 16(1):34, 2024

2024

[21] [21]

Exploring circulating cell-free dna as a biomarker and as an inducer of aim2-inﬂammasome-mediated inﬂammation in patients with abdominal aortic aneurysm

Susanne Dihlmann, Carolin Kaduk, Karola H Passek, Anja Spieler, Dittmar Böckler, and Andreas S Peters. Exploring circulating cell-free dna as a biomarker and as an inducer of aim2-inﬂammasome-mediated inﬂammation in patients with abdominal aortic aneurysm. Scientiﬁc Reports , 15(1):20196, 2025

2025

[22] [22]

Einstein, Nathan Liang, Meenakshi Malhotra, Alexey Aleshin, Solomon Moshkevich, Paul R

David J. Einstein, Nathan Liang, Meenakshi Malhotra, Alexey Aleshin, Solomon Moshkevich, Paul R. Billings, and Eirini Pectasides. Assessment of molecular remission in oligometastatic esophageal cancer with a personalized circulating tumor dna assay. JCO Precision Oncology , (4):239–243, 2020. PMID: 35050735

2020

[23] [23]

Analysis of serum cfdna concentration and integrity before and after surgery in patients with lung cancer

Yihui Fan, Minxin Shi, Saihua Chen, Guanjun Ju, Lingxian g Chen, Haimin Lu, Jian Chen, and Shiying Zheng. Analysis of serum cfdna concentration and integrity before and after surgery in patients with lung cancer. Cellular and Molecular Biology, 65(6):56–63, 2019

2019

[24] [24]

Whole-genome bisulﬁte sequencing analysis of circulating tumour dna for the detection and molecular classiﬁcation of cancer

Yibo Gao, Hengqiang Zhao, Ke An, Zongzhi Liu, Luo Hai, Renda Li, Y ang Zhou, W eipeng Zhao, Y ongsheng Jia, Nan W u, et al. Whole-genome bisulﬁte sequencing analysis of circulating tumour dna for the detection and molecular classiﬁcation of cancer. Clinical and Translational Medicine, 12(8):e1014, 2022

2022

[25] [25]

Cell-free dna in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls

Mary Beth Giacona, George C Ruben, Kenneth A Iczkowski, Thomas B Roos, Donna M Porter, and George D Sorenson. Cell-free dna in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas, 17(1):89–97, 1998

1998

[26] [26]

Exposure-inducible genes may contribute to missingness in rnaseq-based gene expression analyses

Olga Y Gorlova, Ivan P Gorlov, R Taylor Ripley, Chao Cheng, Y afang Li, Bo Peng, Y anhong Liu, Hee-Jin Jang, Sung W ook Kang, Claire Lee, et al. Exposure-inducible genes may contribute to missingness in rnaseq-based gene expression analyses. Scientiﬁc Reports , 15(1):30889, 2025

2025

[27] [27]

Bisulﬁte genomic sequencing: systematic investigation of critical experimental parameters

Christoph Grunau, SJ Clark, and André Rosenthal. Bisulﬁte genomic sequencing: systematic investigation of critical experimental parameters. Nucleic acids research , 29(13):e65–e65, 2001

2001

[28] [28]

Cel l- free dna and apoptosis: how dead cells inform about the living

Ellen Heitzer, Lisa Auinger, and Michael R Speicher. Cel l- free dna and apoptosis: how dead cells inform about the living. Trends in molecular medicine , 26(5):519–528, 2020

2020

[29] [29]

Deciphering response dynamics and treatment resistance from circulati ng tumor dna after car t-cells in multiple myeloma

Hitomi Hosoya, Mia Carleton, Kailee Tanaka, Brian Sword er, Shriya Syal, Bita Sahaf, Alisha M Maltos, Oscar Silva, Henning Stehr, V anna Hovanky, et al. Deciphering response dynamics and treatment resistance from circulati ng tumor dna after car t-cells in multiple myeloma. Nature Communications, 16(1):1824, 2025

2025

[30] [30]

Prediction of dna methylation based on multi-dimensional feature encoding and double convolutional fully connected convolutional neural network

W enxing Hu, Lixin Guan, and Mengshan Li. Prediction of dna methylation based on multi-dimensional feature encoding and double convolutional fully connected convolutional neural network. PLoS Computational Biology, 19(8):e1011370, 2023

2023

[31] [31]

Plasma circulating cell-free dna integrity as a promising biomark er for diagnosis and surveillance in patients with hepatocell ular carcinoma

Ao Huang, Xin Zhang, Shao-Lai Zhou, Y a Cao, Xiao-W u Huang, Jia Fan, Xin-Rong Y ang, and Jian Zhou. Plasma circulating cell-free dna integrity as a promising biomark er for diagnosis and surveillance in patients with hepatocell ular carcinoma. Journal of Cancer , 7(13):1798, 2016. 14

2016

[32] [32]

Bioinformatics analysis for circulating cell-free dna in c ancer

Chiang-Ching Huang, Meijun Du, and Liang W ang. Bioinformatics analysis for circulating cell-free dna in c ancer. Cancers, 11(6):805, 2019

2019

[33] [33]

Getting ready for the european health data space (ehds): Iderha’s plan to align with the latest ehd s requirements for the secondary use of health data

Rada Hussein, Irina Balaur, Anja Burmann, Hanna Ćwiek- Kupczyńska, Y ojana Gadiya, Soumyabrata Ghosh, Prabath Jayathissa, Florian Katsch, Andreas Kremer, Jaakko Lähteenmäki, et al. Getting ready for the european health data space (ehds): Iderha’s plan to align with the latest ehd s requirements for the secondary use of health data. Open Research Europe, 4...

2024

[34] [34]

Transforming cancer screening: the potential of multi-can cer early detection (mced) technologies

Mitsuho Imai, Y oshiaki Nakamura, and Takayuki Y oshino. Transforming cancer screening: the potential of multi-can cer early detection (mced) technologies. International Journal of Clinical Oncology , 30(2):180–193, 2025

2025

[35] [35]

Deconvolution of cell-free dna in cancer liquid biopsy using a deep autoencoder

Felix Jackson and Thomas Lukasiewicz. Deconvolution of cell-free dna in cancer liquid biopsy using a deep autoencoder. In Proceedings of the 14th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics , pages 1–6, 2023

2023

[36] [36]

Dna fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells

Sabine Jahr, Hannes Hentze, Sabine Englisch, Dieter Har dt, Frank O Fackelmayer, Rolf-Dieter Hesch, and Rolf Knippers. Dna fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer research, 61(4):1659–1665, 2001

2001

[37] [37]

Leveraging cfdna fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma

Zichen Jiao, Xiaoqiang Zhang, Y ulong Xuan, Xiaoming Shi , Zirui Zhang, Ao Y u, Ningyou Li, Shanshan Y ang, Xiaofeng He, Gefei Zhao, et al. Leveraging cfdna fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma. Cell Reports Medicine , 5(8), 2024

2024

[38] [38]

Detect ing cell-of-origin and cancer-speciﬁc methylation features o f cell- free dna from nanopore sequencing

Efrat Katsman, Shari Orlanski, Filippo Martignano, Ila na Fox-Fisher, Ruth Shemer, Y uval Dor, A viad Zick, Amir Eden, Iacopo Petrini, Silvestro G Conticello, et al. Detect ing cell-of-origin and cancer-speciﬁc methylation features o f cell- free dna from nanopore sequencing. Genome Biology , 23(1):158, 2022

2022

[39] [39]

Deep learning model integrating cfdna methylation and fragment size proﬁles for lung cancer diagnosis

Minjung Kim, Juntae Park, Seonghee Oh, Byeong-Ho Jeong, Y uree Byun, Sun Hye Shin, Y unjoo Im, Jong Ho Cho, and Eun-Hae Cho. Deep learning model integrating cfdna methylation and fragment size proﬁles for lung cancer diagnosis. Scientiﬁc reports , 14(1):14797, 2024

2024

[40] [40]

To impute or not to impute in untargeted metabolomics that is the compositional question

Dennis D Krutkin, Sydney Thomas, Simone Zuﬀa, Prajit Rajkumar, Rob Knight, Pieter C Dorrestein, and Scott T Kelley. To impute or not to impute in untargeted metabolomics that is the compositional question. Journal of the American Society for Mass Spectrometry , 36(4):742– 759, 2025

2025

[41] [41]

Single-molecule methylation proﬁles of cell-free dna in ca ncer with nanopore sequencing

Billy T Lau, Alison Almeda, Marie Schauer, Madeline McNamara, Xiangqi Bai, Qingxi Meng, Mira Partha, Susan M Grimes, HoJoon Lee, Gregory M Heestand, et al. Single-molecule methylation proﬁles of cell-free dna in ca ncer with nanopore sequencing. Genome Medicine , 15(1):33, 2023

2023

[42] [42]

Impact of clinical variables on cfdna fragmentomic signatures and their potential as confounder s in cancer detection

Tae-Rim Lee, Eun Hye Cho, Jin Mo Ahn, Junnam Lee, Chang-Seok Ki, Byeong-Ho Jeong, Min-Jung Kwon, and Eun-Hae Cho. Impact of clinical variables on cfdna fragmentomic signatures and their potential as confounder s in cancer detection. Clinical Chemistry , 72(2):254–265, 2026

2026

[43] [43]

Free dna in the serum of cancer patients and the eﬀect of therapy

SA Leon, B Shapiro, DM Sklaroﬀ, and MJ Y aros. Free dna in the serum of cancer patients and the eﬀect of therapy. Cancer research, 37(3):646–650, 1977

1977

[44] [44]

Dismir: Deep learning-based noninvasive cancer detection by integrating dna sequence and methylation information of individual cell-free dna reads

Jiaqi Li, Lei W ei, Xianglin Zhang, W ei Zhang, Haochen W ang, Bixi Zhong, Zhen Xie, Hairong Lv, and Xiaowo W ang. Dismir: Deep learning-based noninvasive cancer detection by integrating dna sequence and methylation information of individual cell-free dna reads. Brieﬁngs in bioinformatics , 22(6), 2021

2021

[45] [45]

Comprehensive tissue deconvolution of cell-free dna by deep learning for disease diagnosis and monitoring

Shuo Li, W eihua Zeng, Xiaohui Ni, Qiao Liu, W enyuan Li, Mary L Stackpole, Y onggang Zhou, Arjan Gower, Kostyantyn Krysan, Preeti Ahuja, et al. Comprehensive tissue deconvolution of cell-free dna by deep learning for disease diagnosis and monitoring. Proceedings of the National Academy of Sciences , 120(28):e2305236120, 2023

2023

[46] [46]

Detection of dna base modiﬁcations by deep recurrent neural network on oxford nanopore sequencing data

Qian Liu, Li Fang, Guoliang Y u, Depeng W ang, Chuan-Le Xiao, and Kai W ang. Detection of dna base modiﬁcations by deep recurrent neural network on oxford nanopore sequencing data. Nature communications, 10(1):2449, 2019

2019

[47] [47]

Finaleme: Predicting dna methylation by the fragmentation patterns of plasma cell-free dna

Y aping Liu, Sarah C Reed, Christopher Lo, Atish D Choudhury, Heather A Parsons, Daniel G Stover, Gavin Ha, Gregory Gydush, Justin Rhoades, Denisse Rotem, et al. Finaleme: Predicting dna methylation by the fragmentation patterns of plasma cell-free dna. Nature communications , 15(1):2790, 2024

2024

[48] [48]

A dna methylation atlas of normal human cell types

Netanel Loyfer, Judith Magenheim, A yelet Peretz, Gordo n Cann, Joerg Bredno, Agnes Klochendler, Ilana Fox-Fisher, Sapir Shabi-Porat, Merav Hecht, Tsuria Pelet, et al. A dna methylation atlas of normal human cell types. Nature, 613(7943):355–364, 2023

2023

[49] [49]

Autoencoded dna methylation data to predict breast cancer recurrence: Machine learning models and gene-weigh t signiﬁcance

Laura Macías-García, María Martínez-Ballesteros, José María Luna-Romera, José M García-Heredia, Jorge García-Gutiérrez, and José C Riquelme-Santos. Autoencoded dna methylation data to predict breast cancer recurrence: Machine learning models and gene-weigh t signiﬁcance. Artiﬁcial Intelligence in Medicine , 110:101976, 2020

2020

[50] [50]

Post-menopausal breast cancer: from estrogen to androgen receptor

A visek Majumder, Mahavir Singh, and Suresh C Tyagi. Post-menopausal breast cancer: from estrogen to androgen receptor. Oncotarget, 8(60):102739, 2017

2017

[51] [51]

Clinical variables and cell-free dna fragmentomics: Biological and clinical insi ghts

Y asine Malki and Y M Dennis Lo. Clinical variables and cell-free dna fragmentomics: Biological and clinical insi ghts. Clinical Chemistry , 72(2):219–221, 02 2026

2026

[52] [52]

Les acides nucleiques du plasma sanguin chez 1 homme

P Mandel. Les acides nucleiques du plasma sanguin chez 1 homme. CR Seances Soc Biol Fil , 142:241–243, 1948

1948

[53] [53]

The european health data space

J Scott Marcus, Bertin Martens, Christophe Carugati, An ne Bucher, and Ilsa Godlovitch. The european health data space. IPOL| policy department for economic, scientiﬁc and quality of life policies, European Parliament Policy Department studies , 2022

2022

[54] [54]

Clinical value of plasma cfdna concentration and integrity in breast cancer patients

Y ajun Miao, Yingrui Fan, Liang Zhang, Tingting Ma, and Rong Li. Clinical value of plasma cfdna concentration and integrity in breast cancer patients. Cellular and Molecular Biology, 65(6):64–72, 2019

2019

[55] [55]

Preoperative cell-free dna concentration in plasma as a diagnostic and prognostic biomarker of clear cell renal cell carcinoma

Tomasz Milecki, Katarzyna Kluzek, Natalia Pstrąg, Andr zej Antczak, W ojciech Cieślikowski, Mateusz Wichtowski, Łukasz Kuncman, Zbigniew Kwias, and Joanna W esoły. Preoperative cell-free dna concentration in plasma as a diagnostic and prognostic biomarker of clear cell renal cell carcinoma. Contemporary Oncology/Współczesna Onkologia, 27(4):284–291, 2023

2023

[56] [56]

Technology and future of multi-cancer early detection

Danny A Milner Jr and Jochen K Lennerz. Technology and future of multi-cancer early detection. Life, 14(7):833, 2024. 15

2024

[57] [57]

Spalding, Giora Landesberg, A viad Zick, Albert Grinshpun, AM James Shapiro, Markus Grompe, A vigail Dreazan Wittenberg, Benjamin Glaser, Ruth Shemer, Tommy Kaplan, and Y uval Dor

Joshua Moss, Judith Magenheim, Daniel Neiman, Hai Zemmour, Netanel Loyfer, Amit Korach, Y aacov Samet, Myriam Maoz, Henrik Druid, Peter Arner, Keng-Y eh Fu, Endre Kiss, Kirsty L. Spalding, Giora Landesberg, A viad Zick, Albert Grinshpun, AM James Shapiro, Markus Grompe, A vigail Dreazan Wittenberg, Benjamin Glaser, Ruth Shemer, Tommy Kaplan, and Y uval Do...

2018

[58] [58]

An ultrasensitive method for quantitating circulating tumor dna with broad patient coverage

Aaron M Newman, Scott V Bratman, Jacqueline To, Jacob F W ynne, Neville CW Eclov, Leslie A Modlin, Chih Long Liu, Joel W Neal, Heather A W akelee, Robert E Merritt, et al. An ultrasensitive method for quantitating circulating tumor dna with broad patient coverage. Nature medicine , 20(5):548– 554, 2014

2014

[59] [59]

Appraising clinical applicability of studies: mapping and synthesis o f current frameworks, and proposal of the fracas framework and vicort checklist

Quoc Dinh Nguyen, Erica M Moodie, Philippe Desmarais, Robert Goulden, Marie-France Forget, Eric Peters, Sahar Saeed, Mark R Keezer, and Christina W olfson. Appraising clinical applicability of studies: mapping and synthesis o f current frameworks, and proposal of the fracas framework and vicort checklist. BMC medical research methodology , 21(1):248, 2021

2021

[60] [60]

Trong Hieu Nguyen, Nhu Nhat Tan Doan, Trung Hieu Tran, Le Anh Khoa Huynh, Phuoc Loc Doan, Thi Hue Hanh Nguyen, V an Thien Chi Nguyen, Giang Thi Huong Nguyen, Hoai-Nghia Nguyen, Hoa Giang, et al. Tissue of origin detection for cancer tumor using low-depth cfdna samples through combination of tumor-speciﬁc methylation atlas an d genome-wide methylation dens...

2024

[61] [61]

Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation

Michaël Noë, Dimitrios Mathios, Akshaya V Annapragada, Shashikant Koul, Zacharia H Foda, Jamie E Medina, Stephen Cristiano, Christopher Cherry, Daniel C Bruhm, Noushin Niknafs, et al. Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation. Nature communications, 15(1):6690, 2024

2024

[62] [62]

Mai-Britt W orm Ørntoft, Sarah Østrup Jensen, Nadia Øgaard, Tenna V esterman Henriksen, Linnea Ferm, Ib Jarle Christensen, Thomas Reinert, Ole Halfdan Larsen, Hans Jørgen Nielsen, and Claus Lindbjerg Andersen. Age- stratiﬁed reference intervals unlock the clinical potenti al of circulating cell-free dna as a biomarker of poor outcome for healthy individua...

2021

[63] [63]

Metdecode: methylation-based deconvolution of cell-free dna for noninvasive multi-cancer typing

Antoine Passemiers, Stefania Tuveri, Dhanya Sudhakara n, Tatjana Jatsenko, Tina Laga, Kevin Punie, Sigrid Hatse, Sabine Tejpar, An Coosemans, Els V an Nieuwenhuysen, et al. Metdecode: methylation-based deconvolution of cell-free dna for noninvasive multi-cancer typing. Bioinformatics, 40(9):btae522, 2024

2024

[64] [64]

Early detection of renal cell carcinoma: a novel cell-free dna fragmentomic s- based liquid biopsy assay

YL Peng, B Y u, TX Huang, ZH Zhou, H Zhang, WXF Tang, XX Xu, DQ Zhu, R W Y ang, H Bao, et al. Early detection of renal cell carcinoma: a novel cell-free dna fragmentomic s- based liquid biopsy assay. ESMO open , 10(7):105323, 2025

2025

[65] [65]

Artiﬁcial intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine

Karishma Sahoo, Prakash Lingasamy, Masuma Khatun, Sajitha Lulu Sudhakaran, Andres Salumets, Vino Sundararajan, and Vijayachitra Modhukur. Artiﬁcial intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine. Epigenetics & Chromatin, 18(1):35, 2025

2025

[66] [66]

Computational challenges in detection of cancer using cell-free dna methylation

Madhu Sharma, Rohit Kumar V erma, Sunil Kumar, and Vibhor Kumar. Computational challenges in detection of cancer using cell-free dna methylation. Computational and Structural Biotechnology Journal , 20:26–39, 2022

2022

[67] [67]

Development of a deep learning model for cancer diagnosis by inspecting cell-free dna end-motifs

Hongru Shen, Meng Y ang, Jilei Liu, Kexin Chen, and Xiangchun Li. Development of a deep learning model for cancer diagnosis by inspecting cell-free dna end-motifs. NPJ Precision Oncology, 8(1):160, 2024

2024

[68] [68]

Integrating liquid biopsies into the management of cancer

Giulia Siravegna, Silvia Marsoni, Salvatore Siena, and Alberto Bardelli. Integrating liquid biopsies into the management of cancer. Nature reviews Clinical oncology , 14(9):531–548, 2017

2017

[69] [69]

Circulating tumor nucleic acids: biology, release mechani sms, and clinical relevance

Pavel Stejskal, Hani Goodarzi, Josef Srovnal, Marián Hajdúch, Laura J van’t V eer, and Mark Jesus M Magbanua. Circulating tumor nucleic acids: biology, release mechani sms, and clinical relevance. Molecular cancer, 22(1):15, 2023

2023

[70] [70]

Genome-wide cfdna methylation proﬁling reveals robust hypermethylation signatures in ovarian cancer

Simone Karlsson Terp, Karen Guldbrandsen, Malene Pontoppidan Stoico, Lasse Ringsted Mark, Anna Poulsgaard Frandsen, Karen Dybkær, and Inge Søkilde Pedersen. Genome-wide cfdna methylation proﬁling reveals robust hypermethylation signatures in ovarian cancer. Cancers, 17(12):2026, 2025

2026

[71] [71]

Origins, structures, and functions of circulatin g dna in oncology

Alain R Thierry, S El Messaoudi, PB Gahan, P Anker, and M Stroun. Origins, structures, and functions of circulatin g dna in oncology. Cancer and metastasis reviews , 35:347– 376, 2016

2016

[72] [72]

Artiﬁcial intelligence and machine learning i n cell-free-dna-based diagnostics

WH Adrian Tsui, Spencer C Ding, Peiyong Jiang, and YM Dennis Lo. Artiﬁcial intelligence and machine learning i n cell-free-dna-based diagnostics. Genome Research, 35(1):1– 19, 2025

2025

[73] [73]

There is no such thing as a validated prediction model

Ben V an Calster, Ewout W Steyerberg, Laure W ynants, and Maarten V an Smeden. There is no such thing as a validated prediction model. BMC medicine , 21(1):70, 2023

2023

[74] [74]

Critical factors in the analytical work ﬂow of circulating tumor dna-based molecular proﬁling

Paul van der Leest and Ed Schuuring. Critical factors in the analytical work ﬂow of circulating tumor dna-based molecular proﬁling. Clinical Chemistry , 70(1):220–233, 01 2024

2024

[75] [75]

Cancer treatment monitoring using cell-free dna fragmentomes

Iris van’t Erve, Bahar Alipanahi, Keith Lumbard, Zachar y L Skidmore, Lorenzo Rinaldi, Laurel K Millberg, Jacob Carey, Bryan Chesnick, Stephen Cristiano, Carter Portwood , et al. Cancer treatment monitoring using cell-free dna fragmentomes. Nature communications, 15(1):8801, 2024

2024

[76] [76]

Liquid biopsie s come of age: towards implementation of circulating tumour dna

Jonathan CM W an, Charles Massie, Javier Garcia-Corbach o, Florent Mouliere, James D Brenton, Carlos Caldas, Simon Pacey, Richard Baird, and Nitzan Rosenfeld. Liquid biopsie s come of age: towards implementation of circulating tumour dna. Nature Reviews Cancer , 17(4):223–238, 2017

2017

[77] [77]

Increased plasma dna integrity in cancer patients

Brant G W ang, Han-Y ao Huang, Y u-Chi Chen, Robert E Bristow, Keyanunoosh Kassauei, Chih-Chien Cheng, Richard Roden, Lori J Sokoll, Daniel W Chan, and Ie-Ming Shih. Increased plasma dna integrity in cancer patients. Cancer research, 63(14):3966–3968, 2003

2003

[78] [78]

cfdecon: Accurate and interpretable methylation-based ce ll type deconvolution for cell-free dna

Yixuan W ang, Jiayi Li, Jingqi Li, Shen Y ang, Y uhan Huang, Xinyuan Liu, Yimin Fan, Irwin King, Y umei Li, and Y u Li. cfdecon: Accurate and interpretable methylation-based ce ll type deconvolution for cell-free dna. bioRxiv, pages 2025–02, 2025

2025

[79] [79]

The analysis of cell-free dna 16 concentrations and integrity in serum of initial and treate d of lymphoma patients

Jianqiu W u, W eiyan Tang, Laiquan Huang, Ning Hou, Jing W u, Xianfeng Cheng, Dawei Ma, Pudong Qian, Qian Shen, W enjie Guo, et al. The analysis of cell-free dna 16 concentrations and integrity in serum of initial and treate d of lymphoma patients. Clinical Biochemistry , 63:59–65, 2019

2019

[80] [80]

A systematic review of biologically-informed deep learning models for cancer: fundamental trends for encoding and interpreting oncology data

Magdalena W ysocka, Oskar W ysocki, Marie Zuﬀerey, Dónal Landers, and André Freitas. A systematic review of biologically-informed deep learning models for cancer: fundamental trends for encoding and interpreting oncology data. BMC bioinformatics , 24(1):198, 2023

2023